Cancer Pain - Pipeline Review - H1 2014





Published: March 2014 | Pages: 146 | Format: PDF

 Summary 

 Global Markets Direct’s, ‘Cancer Pain - Pipeline Review, H1 2014’, provides an overview of the Cancer Pain’s therapeutic pipeline. 

 This report provides comprehensive information on the therapeutic development for Cancer Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cancer Pain and special features on late-stage and discontinued projects. 

 Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. 

 The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. 

 Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. 

 Scope 

 

  •  The report provides a snapshot of the global therapeutic landscape of Cancer Pain 
  •  The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities  
  •  The report reviews key players involved in the therapeutics development for Cancer Pain and enlists all their major and minor projects 
  •  The report summarizes all the dormant and discontinued pipeline projects  
  •  A review of the Cancer Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
  •  Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
  •  A detailed assessment of monotherapy and combination therapy pipeline projects 
  •  Coverage of the Cancer Pain pipeline on the basis of target, MoA, route of administration and molecule type 
  •  Latest news and deals relating related to pipeline products 

 

 Reasons to buy 

 

  •  Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies 
  •  Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
  •  Develop strategic initiatives by understanding the focus areas of leading companies 
  •  Identify and understand important and diverse types of therapeutics under development for Cancer Pain 
  •  Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline 
  •  Devise corrective measures for pipeline projects by understanding Cancer Pain pipeline depth and focus of Indication therapeutics 
  •  Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope 
  •  Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline 

 

 Table of Contents 

 Introduction 10 

 Global Markets Direct Report Coverage 10 

 Cancer Pain Overview 11 

 Therapeutics Development 12 

 Pipeline Products for Cancer Pain - Overview 12 

 Pipeline Products for Cancer Pain - Comparative Analysis 13 

 Cancer Pain - Therapeutics under Development by Companies 14 

 Cancer Pain - Therapeutics under Investigation by Universities/Institutes 18 

 Cancer Pain - Pipeline Products Glance 19 

 Late Stage Products 19 

 Clinical Stage Products 20 

 Early Stage Products 21 

 Unknown Stage Products 22 

 Cancer Pain - Products under Development by Companies 23 

 Cancer Pain - Products under Investigation by Universities/Institutes 25 

 Cancer Pain - Companies Involved in Therapeutics Development 26 

 Amgen Inc. 26 

 AstraZeneca PLC 27 

 BioDelivery Sciences International, Inc. 28 

 Nektar Therapeutics 29 

 Daiichi Sankyo Company, Limited 30 

 Egalet Corporation 31 

 Aphios Corporation 32 

 AcelRx Pharmaceuticals, Inc. 33 

 Nippon Kayaku Co., Ltd. 34 

 Nippon Shinyaku Co., Ltd. 35 

 Orion Oyj 36 

 Pfizer Inc. 37 

 Zeria Pharmaceutical Co Ltd 38 

 GW Pharmaceuticals plc 39 

 IntelGenx Corp. 40 

 Benitec Biopharma Limited 41 

 Kolon Life Science, Inc. 42 

 Teikoku Seiyaku Co., Ltd. 43 

 BioAlliance Pharma SA 44 

 tesa Labtec GmbH 45 

 Colby Pharmaceutical Company 46 

 Grunenthal GmbH 47 

 AngioChem Inc. 48 

 WEX Pharmaceuticals Inc. 49 

 Virobay Inc. 50 

 QRxPharma Limited 51 

 Winston Pharmaceuticals, Inc. 52 

 Encore Therapeutics Inc. 53 

 Afferent Pharmaceuticals, Inc. 54 

 Relevare Pharmaceuticals Ltd. 55 

 Northern Light Pharmaceuticals AB 56 

 Cancer Pain - Therapeutics Assessment 57 

 Assessment by Monotherapy Products 57 

 Assessment by Combination Products 58 

 Assessment by Target 59 

 Assessment by Mechanism of Action 62 

 Assessment by Route of Administration 65 

 Assessment by Molecule Type 67 

 Drug Profiles 69 

 fentanyl citrate - Drug Profile 69 

 Product Description 69 

 Mechanism of Action 69 

 R&D Progress 69 

 nabiximols - Drug Profile 70 

 Product Description 70 

 Mechanism of Action 70 

 R&D Progress 70 

 Tetrodotoxin - Drug Profile 73 

 Product Description 73 

 Mechanism of Action 73 

 R&D Progress 73 

 cebranopadol - Drug Profile 75 

 Product Description 75 

 Mechanism of Action 75 

 R&D Progress 75 

 tramadol hydrochloride SR - Drug Profile 77 

 Product Description 77 

 Mechanism of Action 77 

 R&D Progress 77 

 TK-641 - Drug Profile 79 

 Product Description 79 

 Mechanism of Action 79 

 R&D Progress 79 

 tapentadol hydrochloride ER - Drug Profile 80 

 Product Description 80 

 Mechanism of Action 80 

 R&D Progress 80 

 hydromorphone - Drug Profile 83 

 Product Description 83 

 Mechanism of Action 83 

 R&D Progress 83 

 tanezumab - Drug Profile 84 

 Product Description 84 

 Mechanism of Action 84 

 R&D Progress 84 

 saracatinib - Drug Profile 86 

 Product Description 86 

 Mechanism of Action 86 

 R&D Progress 86 

 (morphine + oxycodone) CR - Drug Profile 88 

 Product Description 88 

 Mechanism of Action 88 

 R&D Progress 88 

 ARX-02 - Drug Profile 89 

 Product Description 89 

 Mechanism of Action 89 

 R&D Progress 89 

 morphine sulfate ER - Drug Profile 91 

 Product Description 91 

 Mechanism of Action 91 

 R&D Progress 91 

 fulranumab - Drug Profile 93 

 Product Description 93 

 Mechanism of Action 93 

 R&D Progress 93 

 sufentanil - Drug Profile 95 

 Product Description 95 

 Mechanism of Action 95 

 R&D Progress 95 

 dexmedetomidine hydrochloride - Drug Profile 96 

 Product Description 96 

 Mechanism of Action 96 

 R&D Progress 96 

 fentanyl - Drug Profile 98 

 Product Description 98 

 Mechanism of Action 98 

 R&D Progress 98 

 PGN-202 - Drug Profile 99 

 Product Description 99 

 Mechanism of Action 99 

 R&D Progress 99 

 fentanyl citrate SR - Drug Profile 100 

 Product Description 100 

 Mechanism of Action 100 

 R&D Progress 100 

 leconotide - Drug Profile 101 

 Product Description 101 

 Mechanism of Action 101 

 R&D Progress 101 

 dronabinol - Drug Profile 102 

 Product Description 102 

 Mechanism of Action 102 

 R&D Progress 102 

 VBY-825 - Drug Profile 103 

 Product Description 103 

 Mechanism of Action 103 

 R&D Progress 103 

 zucapsaicin - Drug Profile 104 

 Product Description 104 

 Mechanism of Action 104 

 R&D Progress 104 

 ANG-2002 - Drug Profile 106 

 Product Description 106 

 Mechanism of Action 106 

 R&D Progress 106 

 Z-360 - Drug Profile 107 

 Product Description 107 

 Mechanism of Action 107 

 R&D Progress 107 

 ddRNAi Program For Cancer-Associated Pain - Drug Profile 108 

 Product Description 108 

 Mechanism of Action 108 

 R&D Progress 108 

 NKTR-192 - Drug Profile 110 

 Product Description 110 

 Mechanism of Action 110 

 R&D Progress 110 

 buprenorphine hydrochloride ER - Drug Profile 111 

 Product Description 111 

 Mechanism of Action 111 

 R&D Progress 111 

 AF-353 - Drug Profile 112 

 Product Description 112 

 Mechanism of Action 112 

 R&D Progress 112 

 INT-0028 - Drug Profile 114 

 Product Description 114 

 Mechanism of Action 114 

 R&D Progress 114 

 DD-04107 - Drug Profile 115 

 Product Description 115 

 Mechanism of Action 115 

 R&D Progress 115 

 QX-314 - Drug Profile 116 

 Product Description 116 

 Mechanism of Action 116 

 R&D Progress 116 

 ifenprodil - Drug Profile 117 

 Product Description 117 

 Mechanism of Action 117 

 R&D Progress 117 

 Calpastatin - Drug Profile 118 

 Product Description 118 

 Mechanism of Action 118 

 R&D Progress 118 

 Small Molecule To Antagonize Chemokine Receptor For Cancer Pain - Drug Profile 119 

 Product Description 119 

 Mechanism of Action 119 

 R&D Progress 119 

 KLS-2010 - Drug Profile 120 

 Product Description 120 

 Mechanism of Action 120 

 R&D Progress 120 

 Ph Alpha-1-Beta - Drug Profile 121 

 Product Description 121 

 Mechanism of Action 121 

 R&D Progress 121 

 BBI-11008 - Drug Profile 122 

 Product Description 122 

 Mechanism of Action 122 

 R&D Progress 122 

 CPC-703 - Drug Profile 123 

 Product Description 123 

 Mechanism of Action 123 

 R&D Progress 123 

 Cancer Pain - Recent Pipeline Updates 124 

 Cancer Pain - Dormant Projects 138 

 Cancer Pain - Discontinued Products 139 

 Cancer Pain - Product Development Milestones 140 

 Featured News & Press Releases 140 

 Feb 18, 2014: Preclinical Data on Angiochem Pain Program Published in Journal of Clinical Investigation 140 

 Feb 10, 2014: Sorrento Therapeutics Expands its Exclusive Rights to Cynviloq to Include Australia, Canada and Mexico 140 

 Dec 05, 2013: Orion settles patent dispute over the proprietary drug Precedex 141 

 Jul 29, 2013: BioDelivery Sciences Announces Regulatory Approval of ONSOLIS in Taiwan 141 

 May 10, 2013: Durect Announces Pfizer's Update On Investigational Pain Drug Remoxy 142 

 May 09, 2013: Purdue Pharma To Present Data Regarding Long-Term Opioid Therapy At APS Annual Meeting 142 

 Apr 05, 2013: Phosphagenics Receives Approval To Conduct Clinical Study Of Oxycodone Patch At Royal Adelaide Hospital 143 

 Apr 03, 2013: GW Pharma Receives US Patent Allowance For Delivery Of Sativex Formulation 143 

 Feb 14, 2013: US Federal Court Validates Cephalon’s Fentora Patents 144 

 Oct 15, 2012: BioDelivery Sciences Announces Launch Of Breakyl In EU 144 

 Appendix 145 

 Methodology 145 

 Coverage 145 

 Secondary Research 145 

 Primary Research 145 

 Expert Panel Validation 145 

 Contact Us 146 

 Disclaimer 146 

  

 List of Tables 

 Number of Products under Development for Cancer Pain, H1 2014 12 

 Number of Products under Development for Cancer Pain - Comparative Analysis, H1 2014 13 

 Number of Products under Development by Companies, H1 2014 15 

 Number of Products under Development by Companies, H1 2014 (Contd..1) 16 

 Number of Products under Development by Companies, H1 2014 (Contd..2) 17 

 Number of Products under Investigation by Universities/Institutes, H1 2014 18 

 Comparative Analysis by Late Stage Development, H1 2014 19 

 Comparative Analysis by Clinical Stage Development, H1 2014 20 

 Comparative Analysis by Early Stage Development, H1 2014 21 

 Comparative Analysis by Unknown Stage Development, H1 2014 22 

 Products under Development by Companies, H1 2014 23 

 Products under Development by Companies, H1 2014 (Contd..1) 24 

 Products under Investigation by Universities/Institutes, H1 2014 25 

 Cancer Pain - Pipeline by Amgen Inc., H1 2014 26 

 Cancer Pain - Pipeline by AstraZeneca PLC, H1 2014 27 

 Cancer Pain - Pipeline by BioDelivery Sciences International, Inc., H1 2014 28 

 Cancer Pain - Pipeline by Nektar Therapeutics, H1 2014 29 

 Cancer Pain - Pipeline by Daiichi Sankyo Company, Limited, H1 2014 30 

 Cancer Pain - Pipeline by Egalet Corporation, H1 2014 31 

 Cancer Pain - Pipeline by Aphios Corporation, H1 2014 32 

 Cancer Pain - Pipeline by AcelRx Pharmaceuticals, Inc., H1 2014 33 

 Cancer Pain - Pipeline by Nippon Kayaku Co., Ltd., H1 2014 34 

 Cancer Pain - Pipeline by Nippon Shinyaku Co., Ltd., H1 2014 35 

 Cancer Pain - Pipeline by Orion Oyj, H1 2014 36 

 Cancer Pain - Pipeline by Pfizer Inc., H1 2014 37 

 Cancer Pain - Pipeline by Zeria Pharmaceutical Co Ltd, H1 2014 38 

 Cancer Pain - Pipeline by GW Pharmaceuticals plc, H1 2014 39 

 Cancer Pain - Pipeline by IntelGenx Corp., H1 2014 40 

 Cancer Pain - Pipeline by Benitec Biopharma Limited, H1 2014 41 

 Cancer Pain - Pipeline by Kolon Life Science, Inc., H1 2014 42 

 Cancer Pain - Pipeline by Teikoku Seiyaku Co., Ltd., H1 2014 43 

 Cancer Pain - Pipeline BioAlliance Pharma SA, H1 2014 44 

 Cancer Pain - Pipeline by tesa Labtec GmbH, H1 2014 45 

 Cancer Pain - Pipeline by Colby Pharmaceutical Company, H1 2014 46 

 Cancer Pain - Pipeline by Grunenthal GmbH, H1 2014 47 

 Cancer Pain - Pipeline by AngioChem Inc., H1 2014 48 

 Cancer Pain - Pipeline by WEX Pharmaceuticals Inc., H1 2014 49 

 Cancer Pain - Pipeline by Virobay Inc., H1 2014 50 

 Cancer Pain - Pipeline by QRxPharma Limited, H1 2014 51 

 Cancer Pain - Pipeline by Winston Pharmaceuticals, Inc., H1 2014 52 

 Cancer Pain - Pipeline by Encore Therapeutics Inc., H1 2014 53 

 Cancer Pain - Pipeline by Afferent Pharmaceuticals, Inc., H1 2014 54 

 Cancer Pain - Pipeline by Relevare Pharmaceuticals Ltd., H1 2014 55 

 Cancer Pain - Pipeline by Northern Light Pharmaceuticals AB, H1 2014 56 

 Assessment by Monotherapy Products, H1 2014 57 

 Assessment by Combination Products, H1 2014 58 

 Number of Products by Stage and Target, H1 2014 61 

 Number of Products by Stage and Mechanism of Action, H1 2014 64 

 Number of Products by Stage and Route of Administration, H1 2014 66 

 Number of Products by Stage and Molecule Type, H1 2014 68 

 Cancer Pain Therapeutics - Recent Pipeline Updates, H1 2014 124 

 Cancer Pain - Dormant Projects, H1 2014 138 

 Cancer Pain - Discontinued Products, H1 2014 139 

  

 List of Figures 

 Number of Products under Development for Cancer Pain, H1 2014 12 

 Number of Products under Development for Cancer Pain - Comparative Analysis, H1 2014 13 

 Number of Products under Development by Companies, H1 2014 14 

 Comparative Analysis by Late Stage Development, H1 2014 19 

 Comparative Analysis by Clinical Stage Development, H1 2014 20 

 Comparative Analysis by Early Stage Products, H1 2014 21 

 Assessment by Monotherapy Products, H1 2014 57 

 Number of Products by Top 10 Target, H1 2014 59 

 Number of Products by Stage and Top 10 Target, H1 2014 60 

 Number of Products by Top 10 Mechanism of Action, H1 2014 62 

 Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 63 

 Number of Products by Top 10 Route of Administration, H1 2014 65 

 Number of Products by Stage and Top 10 Route of Administration, H1 2014 66 

 Number of Products by Top 10 Molecule Type, H1 2014 67 

 Number of Products by Stage and Top 10 Molecule Type, H1 2014 68